Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.02 CAD | -20.00% |
|
-20.00% | -33.33% |
Valuation
Fiscal Period: September | 2023 |
---|---|
Capitalization 1 | 3.202 |
Enterprise Value (EV) 1 | 2.595 |
P/E ratio | -2.45 x |
Yield | - |
Capitalization / Revenue | - |
EV / Revenue | - |
EV / EBITDA | - |
EV / FCF | -3,823,205 x |
FCF Yield | -0% |
Price to Book | 13.6 x |
Nbr of stocks (in thousands) | 80,053 |
Reference price 2 | 0.0400 |
Announcement Date | 1/30/24 |
Income Statement Evolution (Annual data)
Fiscal Period: September | 2021 | 2022 | 2023 |
---|---|---|---|
Net sales | - | - | - |
EBITDA | - | - | - |
EBIT 1 | -0.6837 | -1.13 | -1.178 |
Operating Margin | - | - | - |
Earnings before Tax (EBT) 1 | -1.948 | -1.132 | -1.278 |
Net income 1 | -1.948 | -1.132 | -1.278 |
Net margin | - | - | - |
EPS 2 | -0.0349 | -0.0149 | -0.0163 |
Free Cash Flow | - | -0.3612 | -0.6788 |
FCF margin | - | - | - |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 1/18/22 | 1/30/23 | 1/30/24 |
Balance Sheet Analysis
Fiscal Period: September | 2021 | 2022 | 2023 |
---|---|---|---|
Net Debt 1 | - | - | - |
Net Cash position 1 | 2.36 | 1.57 | 0.61 |
Leverage (Debt/EBITDA) | - | - | - |
Free Cash Flow | - | -0.36 | -0.68 |
ROE (net income / shareholders' equity) | - | -65% | -172% |
ROA (Net income/ Total Assets) | - | -35.3% | -64.6% |
Assets 1 | - | 3.212 | 1.977 |
Book Value Per Share 2 | 0.0300 | 0.0200 | 0 |
Cash Flow per Share 2 | 0.0300 | 0.0200 | 0.0100 |
Capex | - | - | - |
Capex / Sales | - | - | - |
Announcement Date | 1/18/22 | 1/30/23 | 1/30/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-33.33% | 1.48M | |
+22.53% | 3,425B | |
+17.88% | 93B | |
+15.82% | 86.49B | |
+50.55% | 57.57B | |
-20.24% | 50.05B | |
+38.23% | 48.65B | |
-23.39% | 47.44B | |
+76.52% | 41.06B | |
-4.63% | 26.86B |
- Stock Market
- Equities
- DMED Stock
- Financials Diagnamed Holdings Corp.